{"id":1020275,"date":"2026-11-12T09:23:32","date_gmt":"2026-11-12T14:23:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-reports-third-quarter-2026-financial-results-and-provides-business-update\/"},"modified":"2026-11-12T09:23:32","modified_gmt":"2026-11-12T14:23:32","slug":"generate-biomedicines-reports-third-quarter-2026-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/generate-biomedicines-reports-third-quarter-2026-financial-results-and-provides-business-update\/","title":{"rendered":"Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year<\/em>\n <\/p>\n

\n A single dose of GB-0895 produced sustained pharmacological activity for at least six months in COPD<\/em>\n <\/p>\n

\n Zealand Pharma collaboration provides $30 million upfront, $35 million in early preclinical milestones and nearly $1.2 billion in total potential milestones, plus tiered royalties<\/em>\n <\/p>\n

\n Anthropic collaboration builds on AI agent\u2013guided CAR T research yielding smaller signaling domains with improved function in preclinical studies<\/em>\n <\/p>\n

\n Oncology clinical programs advance with second-cohort enrollment for GB-4362 in advanced urothelial cancer and first-patient dosing of GB-5267 in platinum-resistant ovarian cancer <\/em>\n <\/p>\n

\n Cash, cash equivalents, and marketable securities of $404.2 million as of Sept. 30, 2026<\/em>\n <\/p>\n

SOMERVILLE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) — Generate Biomedicines, Inc. (Nasdaq: GENB) (\u201cGenerate\u201d) today reported financial results for the third quarter ended Sept. 30, 2026, and provided an update on recent business progress.<\/p>\n

\u201cOur third quarter results reflect both strong execution across all of our clinical programs and our continued efforts to push the frontiers of programmable biology and therapeutic intelligence,\u201d said Mike Nally, chief executive officer of Generate Biomedicines. \u201cWe are making strong progress with GB-0895 in severe asthma, and the data we shared at ERS in COPD further demonstrated the sustained pharmacological activity to support robust modulation of key biomarkers and twice-a-year dosing. At the same time, our scientists are extending the impact of our platform, from new CAR T engineering to our collaboration with Anthropic on agentic science. We start with what a therapy needs to do, then engineer and test the biology to get there.\u201d<\/p>\n

\n Recent Progress<\/strong>\n <\/p>\n

\n GB-0895 in severe asthma and COPD<\/strong>\n <\/p>\n

GB-0895, Generate\u2019s most advanced internal drug candidate, is an investigational anti-TSLP monoclonal antibody engineered with AI for dosing twice a year. The two global Phase 3 SOLAIRIA<\/u><\/a> studies are ongoing in adults and adolescents with severe uncontrolled asthma, and recent Phase 1b results in COPD patients highlight an opportunity to expand into a large and underserved patient population.<\/p>\n

Generate presented three posters on GB-0895 at the European Respiratory Society Congress, held Sept. 5\u20139, 2026, in Barcelona, Spain.<\/p>\n